NJ-TRUE
19.4.2022 08:05:10 CEST | Business Wire | Press release
True , the fastest-growing global platform of innovative talent management products and services, announced today it has appointed Kate Vanek as general manager, international. Kate joins True from BlackRock where she held the dual responsibility of CFO of EMEA and COO of global finance.
In her role, Kate will work closely with True’s global leadership to enhance and expand the firm’s international executive search business and broader platform of talent management products and services including Thrive, Synthesis, and AboveBoard. Kate is London-based and will oversee the international business across EMEA and APAC, which today includes True's offices in Amsterdam, Berlin, Dubai, London, Melbourne, Shanghai, Singapore, Stockholm, Sydney and Tel Aviv.
“Kate has a passion for talent management and a dynamic, inspirational leadership style,” said Joe Riggione , True co-founder and co-CEO. “She’s a high-performance operator who combines her personal and business experiences to connect people and complex global organizations. She is an impressive leader with an extraordinary track record, and we are lucky to have her.”
“I’m thrilled to be joining True during this period of expansion, and I’m excited to help propel True’s vision to build the global talent management firm of the future,” Kate commented. “True’s special culture and commitment to investing in its people, combined with their world-class executive search expertise and cutting-edge platform make it a place I couldn’t be more proud to join.”
“Kate's experience in strategic business building prepares her to expand our offerings globally to meet the needs of our clients who rely on True’s talent expertise and platform to help them grow and thrive,” said Brad Stadler , True co-founder and co-CEO.
Kate Vanek, True’s GM, International
Kate’s background has rich diversity of experience in finance, strategy and business operations, M&A, investor relations, DE&I initiatives, and leadership development. She has managed global teams in leadership roles across a range of industries from financial services, data science, consumer behavior measurement to industrials.
ABOUT TRUE
True is a platform of products and services driving the intelligence behind talent management:
True Search
Global recruitment for board members, c-suite executives, VPs, directors, and other strategic talent. We focus on investment firms, their portfolio companies and public companies seeking transformative growth.
Thrive
Collaborative, real-time talent relationship management software and information services for search firms, in-house recruiters and VC/PE firms looking to make better hiring decisions.
Synthesis
A multi-layered approach to leadership assessment and development, which combines the evaluation methods of elite military units, executive coaching techniques and agile methodology principles.
AboveBoard
True co-founded AboveBoard, a diversity-focused startup bringing unparalleled solutions to the critical need to bring more women and executives of color to leadership roles. With AboveBoard's two-way platform, members get unique visibility to hundreds of opportunities while companies get access to qualified candidates.
True Equity
True Equity provides exposure to high-quality venture capital and growth equity investments. As a value-added talent partner, True Equity makes direct investments alongside premier investors. True Equity Fund I participates in Series A and B investments. True Equity Growth Fund II focuses on late stage venture and growth equity companies.
Vera
Vera is a family of investment funds that backs exceptional entrepreneurs and companies dedicated to changing our collective future through technology at the pre-seed, seed, early, and late stages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005587/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom